2014

The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)

    SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:  
 WX), a leading pharmaceutical, biotechnology and medical device research
 and development outsourcing company with operations in China and the United
 States, announced today that it has acquired a QPatch HT automated patch
 clamp system, the first unit introduced into China by Sophion Bioscience.
 
     The drug discovery process in pharmaceutical companies begins with
 identifying potential targets for new diseases. One important class of
 targets is ion channels that regulate the flow of ions across cellular
 membranes and therefore influence the physiology of all cells. Patch clamp
 is a widely applied gold-standard technique for the study of ion channels.
 Speed and accuracy of automated patch clamp systems are heavily demanded by
 pharmaceutical companies working with development of ion channel-based
 drugs.
 
     The newly introduced QPatch HT is the world's first 48-channel gigaseal
 patch clamp system that can be applied to both voltage-gated and
 ligand-gated ion channels. With its ability to generate thousands of
 high-quality data points daily, QPatch HT is enabling new screening
 paradigms in ion channel drug discovery and safety testing on a truly
 industrial basis. It is claimed to be taking automated patch clamping to a
 new and even more powerful level.
 
     "We hope the acquisition of the QPatch technology will assist WuXi
 PharmaTech in expanding their services into the rapidly increasing fields
 of cardiac safety testing and ion channel drug discovery," commented Frank
 Henrichsen, Vice President Sales and Marketing in Sophion Bioscience, the
 supplier of QPatch HT.
 
     "We are very pleased to have installed the first QPatch HT automated
 patch clamp system in China, and indeed, the first ever such unit in any
 integrated drug and medical device R&D outsourcing service company," Dr.
 Peng Wang, Vice President of Discovery Biology at WuXi PharmaTech, said
 excitedly, "It will greatly enhance our drug R&D service capabilities and
 productivity. We will continue investing in cutting-edge discovery
 technologies as we strive to serve our global clients better."
 
     About WuXi PharmaTech
 
     WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
 device R&D outsourcing company, with operations in China and the United
 States. As a research-driven and customer-focused company, WuXi PharmaTech
 provides pharmaceutical, biotechnology and medical device companies a broad
 and integrated portfolio of laboratory and manufacturing services
 throughout the drug and medical device R&D process. WuXi PharmaTech's
 services are designed to assist its global partners in shortening the cycle
 and lowering the cost of drug and medical device R&D. For more information,
 please visit: http://www.wuxipharmatech.com .
 
 
 

SOURCE WuXi PharmaTech

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.